Normal
Board of Directors

The Company believes that the skills and experience of each director are of the appropriate mix to provide effective governance and management of the business. 

Tim McCarthy
Non-executive Chairman

Mr McCarthy has a 35 year international business career in high growth biotech, healthcare and technology companies. He is currently Chairman and Non-Executive Director for a number of biotech and healthcare related companies, including Incanthera, Harvard Healthcare and Expedeon Holdings. Mr McCarthy is also the former Chief Executive Officer and Finance Director of a number UK listed public and private companies, including Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, Mr McCarthy has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing. A Fellow of the Association of Chartered Certified Accountants, Mr McCarthy has an MBA from Cranfield School of Management.

Dr Franco Di Muzio
Senior Non-Executive Director

Dr. Di Muzio has 40 years experience in the pharmaceutical and other industries, encompassing international management experience in business development, strategic marketing, international finance, M & A and re-engineering businesses. After graduating in Economics and Business in 1963, Dr Di Muzio worked for Colgate Palmolive and Nestle before joining Squibb (now Bristol Myers Squibb) for eight years. Dr Di Muzio became Executive Vice President of BMS' medical equipment and products division, Weck International Inc., in charge of Europe, Asia, Middle East and Africa. In 1990, he joined Glaxo Wellcome plc. (now GlaxoSmithKline plc) in London as Area Managing Director and Head of all GW's business in the Middle East, Africa and Turkey. Following early retirement from Glaxo Wellcome, in the beginning of 1998, he joined Alza International, the then world leader in drug delivery systems, as Managing Director, based in London, in charge of the company's business expansion in all markets outside the US and remained there until the end of 2000. Dr Di Muzio was appointed Interim Chairman in May 2015 due to Richard Warr's ill health and subsequent passing away.

Dimitri F Dimitriou, MSc
Chief Executive Officer & Co-Founder

Dimitri Dimitriou has 25 years’ experience in the pharmaceutical and biotech industry. His past roles include senior director, worldwide business development at GlaxoSmithKline, where his responsibilities included worldwide corporate deals with pharmaceutical and biotech companies. He held a similar role in Europe for Bristol-Myers Squibb. He spent 8 years at Procter & Gamble in senior marketing, R&D and business development positions and began his career at Novartis (Sandoz) in 1987. He is the founder and chief executive officer of DyoDelta Biosciences, a company specialising in transactions between pharma and biotech companies. He has a degree in biochemistry from Chelsea College (now Kings College, London) and an MSc in pathology and toxicology from the Royal Postgraduate Medical School (now Imperial College Medical School).

Dr Robert Zimmer, MD, PhD
President, Chief Science Officer & Co-Founder

Dr. Robert Zimmer was the founder and chief executive officer of both ImmuPharma Switzerland and ImmuPharma France. He is an expert in clinical pharmacology and life cycle management. He was instrumental in developing a substantial number of products for clients including Roche, GlaxoSmithKline, Abbott, Searle, Sanofi-Aventis and Lilly. He began his career in Roche’s headquarters in Basle as coordinator of clinical pharmacology and international clinical leader. He subsequently joined Jago Pharma, the drug delivery company, and became a director and head of research and development at SkyePharma after it acquired JAGO. He obtained his MD at Strasbourg Medical School and his PHD at the University of Aix-Marseille. On 6 May 2015 it was announced Dr Di Muzio had been appointed Interim Chairman due to Richard Warr’s ill health.

Dr Stéphane Méry
Non-Executive Director

Dr Stéphane Méry has extensive experience in the Healthcare industry. He is currently CEO of Contronics Ltd, which designs and sells laboratory monitoring equipments, and until recently he was Partner at Beringea LLP, a $400m US/UK venture capital fund, where he was responsible for healthcare investments in Europe. Previously, he was the Fund Manager/CEO of the Bloomsbury Bioseed Fund, a Biotech and Medtech investment fund, which was behind the birth of successful companies such as Spirogen (sold to MedImmune), Abzema (listed on AIM), and Canbex, (recently sold to Ipsen). Prior to this, Stéphane was Associate Director, Worldwide Business Development, for SmithKline Beecham (GSK) where he was responsible for the negotiation of several major in-license deals and acquisitions. Before GSK, he was involved in the start-up of Double Helix Development, a successful strategic consultancy company specialising in R&D for the biotech and healthcare industry and recently sold to McCann. Just before, he worked as a management consultant at the American consultancy firm, ZS Associates, specialising on sales and marketing within the pharmaceutical industry. Stéphane is a Doctor in Veterinary Medicine, a trained Veterinary Pathologist, specialising in Nasal Toxicology at the Chemical Industry Institute of Toxicology (CIIT) in North Carolina, and holds an MBA from INSEAD (Fontainebleau).

Dr Ajay Agrawal, PhD
Non-Executive Director

Dr Agrawal has 20 years’ experience in the biotech and pharmaceutical industry worldwide. He was a founder of polyMASC Pharmaceuticals plc, London in 1995, the first UK biotech company, derived from a university that was directly listed on AIM, raising approximately $40 million in 1995, and subsequently merged with a NASDAQ-listed company, Valentis Inc (USA) in 1999 to become one of the biggest companies in the delivery of biologics at that time. He currently sits on the editorial advisory board of three international medical journals, Current Drug Delivery, Infectious Disorders- Drug Targets, and Recent Patents on Drug Delivery and Formulation, Bentham Press, California, USA. Dr Agrawal has been a consultant to a number of companies in the sector, including Genovac GmbH (Germany), Qiagen (Germany), PHT Pharma (Italy) and Karo Bio (Sweden). He holds a PhD in Chemistry and has conducted his post-doctoral research in the faculty of Medicine, University of Alberta, Canada and at the Royal Free Hospital in London.

Richard Warr, MA
Co-Founder

Richard Warr was a co-founder and Chairman of ImmuPharma. It was announced in May 2015 that Richard had taken a leave of absence due to ill health. A few months later, in July, Richard unexpectedly passed away.

Dimitri Dimitrou, Chief Executive Director said: "No words can truly convey the deep sadness we feel at Richard’s untimely passing away. Richard will be remembered and missed by all of us at ImmuPharma. As a co-founder of ImmuPharma and a highly valued Chairman and friend, he provided the Board with insightful and considered advice and was instrumental in steering ImmuPharma into the successful Company we have today. All of us at ImmuPharma, associates and advisors who have worked closely with Richard over the years, extend our heartfelt thoughts and deepest sympathy to his wife and family."

Tracy Weimar
Vice President, Operations & Finance

Ms Weimar has spent over 8 years at GlaxoSmithKline and her most recent position there was Director, Worldwide Business Development where she was involved in a number of corporate licensing deals. She has also held a number of positions in health economics, strategy development, sales and marketing.

Ms Weimar was been a non-executive director for the Avon and Wiltshire Mental Health Partnership NHS Trust responsible for ensuring the Trust was accountable to the public for the services it provided and for the public funds it used. She was a member of both the Audit and Remuneration Committees of the Trust.

Prior to joining GlaxoSmithKline, Ms Weimar spent 5 years at Arthur Andersen in San Francisco and London, responsible for a range of consulting and compliance projects.

Ms Weimar holds an MBA from the London Business School and a BA in Economics from the University of California, Berkeley.

ImmuPharma's Board of Directors consists of:

Tim McCarthy
Non-executive Chairman
Dr Robert Zimmer, MD, PhD
President & Chief Science
Officer & Co-founder
Dimitri F Dimitriou, MSc
Chief Executive Director & Co-Founder
Dr Franco Di Muzio
Senior Non-Executive Director
Dr Stéphane Méry
Non-Executive Director

The Board is supported by
Tracy Weimar
Company Secretary
who is not a Board Director.